Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Characterization of antibody variants during process development: the tale of incomplete processing of N-terminal secretion peptide.

Ambrogelly A, Liu YH, Li H, Mengisen S, Yao B, Xu W, Cannon-Carlson S.

MAbs. 2012 Nov-Dec;4(6):701-9. doi: 10.4161/mabs.21614. Epub 2012 Aug 29.

2.

IL-10 elicits IFN╬│-dependent tumor immune surveillance.

Mumm JB, Emmerich J, Zhang X, Chan I, Wu L, Mauze S, Blaisdell S, Basham B, Dai J, Grein J, Sheppard C, Hong K, Cutler C, Turner S, LaFace D, Kleinschek M, Judo M, Ayanoglu G, Langowski J, Gu D, Paporello B, Murphy E, Sriram V, Naravula S, Desai B, Medicherla S, Seghezzi W, McClanahan T, Cannon-Carlson S, Beebe AM, Oft M.

Cancer Cell. 2011 Dec 13;20(6):781-96. doi: 10.1016/j.ccr.2011.11.003.

3.

Mass spectrometric characterization of the isoforms in Escherichia coli recombinant DNA-derived interferon alpha-2b.

Liu YH, Wylie D, Zhao J, Cure R, Cutler C, Cannon-Carlson S, Yang X, Nagabhushan TL, Pramanik BN.

Anal Biochem. 2011 Jan 1;408(1):105-17. doi: 10.1016/j.ab.2010.08.033. Epub 2010 Aug 31.

PMID:
20807495
4.

Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody.

Wang Y, Hailey J, Williams D, Wang Y, Lipari P, Malkowski M, Wang X, Xie L, Li G, Saha D, Ling WL, Cannon-Carlson S, Greenberg R, Ramos RA, Shields R, Presta L, Brams P, Bishop WR, Pachter JA.

Mol Cancer Ther. 2005 Aug;4(8):1214-21.

5.

Characterization of interferon a2B pegylated via carboxyalkylation: a case study.

Wylie DC, Voloch M, Lee S, Liu YH, Cutler C, Larkin B, Cannon-Carlson S.

Methods Mol Biol. 2005;308:337-48. No abstract available.

PMID:
16082046
6.

Characterization of hemodynamic events following intravascular infusion of recombinant adenovirus reveals possible solutions for mitigating cardiovascular responses.

Machemer T, Engler H, Tsai V, Lee S, Cannon-Carlson S, Voloch M, Schluep T, Ravindran S, Vellekamp G, Brin E, Cornell D, Sutjipto S, Wen SF, Horn M, Van Rooijen N, Maneval D, Hutchins B, LaFace D.

Mol Ther. 2005 Aug;12(2):254-63.

7.

Site of pegylation and polyethylene glycol molecule size attenuate interferon-alpha antiviral and antiproliferative activities through the JAK/STAT signaling pathway.

Grace MJ, Lee S, Bradshaw S, Chapman J, Spond J, Cox S, Delorenzo M, Brassard D, Wylie D, Cannon-Carlson S, Cullen C, Indelicato S, Voloch M, Bordens R.

J Biol Chem. 2005 Feb 25;280(8):6327-36. Epub 2004 Dec 13.

8.

Improvement of monoclonal antibody production in hybridoma cells by dimethyl sulfoxide.

Ling WL, Deng L, Lepore J, Cutler C, Cannon-Carlson S, Wang Y, Voloch M.

Biotechnol Prog. 2003 Jan-Feb;19(1):158-62.

PMID:
12573019
9.

Carboxyalkylated histidine is a pH-dependent product of pegylation with SC-PEG.

Wylie DC, Voloch M, Lee S, Liu YH, Cannon-Carlson S, Cutler C, Pramanik B.

Pharm Res. 2001 Sep;18(9):1354-60.

PMID:
11683252
10.

Empty capsids in column-purified recombinant adenovirus preparations.

Vellekamp G, Porter FW, Sutjipto S, Cutler C, Bondoc L, Liu YH, Wylie D, Cannon-Carlson S, Tang JT, Frei A, Voloch M, Zhuang S.

Hum Gene Ther. 2001 Oct 10;12(15):1923-36.

PMID:
11589834
11.

Mass spectrometric mapping of disulfide bonds in recombinant human interleukin-13.

Tsarbopoulos A, Varnerin J, Cannon-Carlson S, Wylie D, Pramanik B, Tang J, Nagabhushan TL.

J Mass Spectrom. 2000 Mar;35(3):446-53.

PMID:
10767776
12.

Expression, purification, and characterization of recombinant human interleukin-13 from NS-O cells.

Cannon-Carlson S, Varnerin J, Tsarbopoulos A, Jenh CH, Cox MA, Chou CC, Connelly N, Zavodny P, Tang JC.

Protein Expr Purif. 1998 Mar;12(2):239-48.

PMID:
9518466
13.

Supplemental Content

Loading ...
Support Center